首页> 外国专利> L-pyroglutamyl-l-prolyl-l-seryl-l-lysyl-l-spartyl-l-alanyl-l-phenylalanyl-l-isoleucyl-glycyl-l-leucyl-l-methioninamide and its acid addition salts with protective groupson the epsilon-amino radical of lysine

L-pyroglutamyl-l-prolyl-l-seryl-l-lysyl-l-spartyl-l-alanyl-l-phenylalanyl-l-isoleucyl-glycyl-l-leucyl-l-methioninamide and its acid addition salts with protective groupson the epsilon-amino radical of lysine

机译:在保护基上的L-焦谷氨酰基-1-脯氨酰基-1-丝氨酰基-1-赖氨酰基-1-琥珀酰-1-丙氨酰基-1-苯丙氨酰基-1-异亮氨酰基-甘氨酰基-1-亮氨酰-1-蛋氨酸酰胺及其酸加成盐与保护基赖氨酸的ε-氨基自由基

摘要

The invention comprises the hendecapeptide pyroglutamyl - prolyl - seryl - lysyl - aspartyl alanyl - phenylalanyl - isoleucyl - glycyl leucyl-methionine amide (wherein all the amino acid residues are of L-configuration), its acid addition salts, and peptide having a protective group on the e -amino radical of the lysine residue and, optionally, a protective group on the end amido group of the pyroglutamine residue and/or a protective group on the b -carboxyl radical of the aspartic acid residue, and the preparation thereof by condensing a suitably protected pyroglutamyl-prolyl-seryl-lysine having, optionally, the carboxyl radical of the lysine residue substituted with a radical reactive with amino radicals to form an amide link with aspartyl-alaryl - phenylalanyl - isoleucyl - glycyl - leucyl-methionine amide, optionally protected, and if desired removing the protecting groups in one or more stages. Protecting groups for the pyroglutamyl residue are, for example, carbobenzoxy, carbo-tertiary-butoxy and p-nitrocarbo benzoxy; for the Ne amino group of lysine, the aforementioned together with phthalyl and formyl; and for the b -carboxyl group benzoyl, p-nitrobenzyl, methyl, ethyl, tertiary-butyl and amido radicals. Groups in the tetrapeptide reactive with amino radicals to form amide linkages are azide, and p-nitrophenyl ester radicals; an asymmetric anhydride of the detetrapept or the reaction product of the tetrapeptide with dicyclohexylcarbodiimide. Pyroglutamyl - prolyl - seryl - (Ne - carbotertiary-butoxy) lysine hydrazide is prepared by condensing carbobenzoxypyroglutamine p-nitrophenyl ester with prolin to give carbobenzoxypyroglutamyl-proline, condensing this with seryl - Ne - carbobenzoxylysine methyl ester to give carbobenzoxypyroglutamyl - prolyl - seryl-lysine methyl ester, hydrogenating this to give the free tetra peptide ester, forming the Ne -carbo - t - butoxy - lysine derivative and reacting the ester with hydrazine. Seryl - Ne - carbobenzoxylysine methyl ester is prepared by condensing N-tritylserine with Ne -carbobenzoxylysine methyl ester and detritylating the protected dipeptide. Aspartyl - alanyl - phenylalanyl - isoleucyl-glycyl - leucyl - methioninamide is prepared from carbobenzoxyphenylalamine p-nitrophenyl ester and isoleucine methyl ester through carbo-benzoxyphenylalanyl - isoleucyl methyl ester, carbobenzoxy - o - benzyloxyaspartyl - isoleucine methyl ester, carbo - tert - butoxy - aspartyl-alanyl - phenylalanyl - isoleucine methyl ester and its hydrazide and carbo-tert-butyoxy-aspartyl - alanyl - phenylalanyl - isoleucyl - glycyl - leucyl - methioninamide, by stepwise addition of an amino acid with liberation of the free amino peptides, the last stage being condensation between a tetra- and a tri-peptide. Glycyl - leucyl - methioninamide is prepared from trityl - glycyl - leucine and methionine amide through the trityl tripeptamide. Pharmaceutical compositions showing hypotensive activity comprise the compounds of the invention with an inert pharmaceutical carrier. Specifications 872,332 and 878,732 are referred to.
机译:本发明包括苯二肽焦谷氨酰-脯氨酰基-丝氨酰-赖氨酰-天冬氨酰丙氨酰-苯丙氨酰-异亮氨酰-甘氨酰亮氨酰-蛋氨酸酰胺(其中所有氨基酸残基均为L-构型),其酸加成盐和具有保护基的肽赖氨酸残基的e-氨基上的残基,以及焦谷氨酰胺残基的末端酰胺基上的保护基和/或天冬氨酸残基的b-羧基上的保护基,及其缩合制备适当保护的焦谷氨酰基-脯氨酰基-丝氨酰-赖氨酸,其赖氨酸残基的羧基任选被与氨基反应的基团取代以与天冬氨酰基-芳基-苯丙氨酰基-异亮氨酰基-甘氨酰基-亮氨酰-蛋氨酸酰胺形成酰胺键,任选地被保护,并且如果需要的话,在一个或多个阶段中除去保护基。焦谷氨酰基残基的保护基是,例如,碳苯甲酰,碳叔叔丁氧基和对硝基碳苄氧基;对于赖氨酸的Ne氨基,上述与邻苯二甲酰基和甲酰基一起;对于β-羧基,苯甲酰基,对硝基苄基,甲基,乙基,叔丁基和酰胺基。在四肽中与氨基反应形成酰胺键的基团是叠氮化物和对硝基苯基酯基。四肽的不对称酸酐或四肽与二环己基碳二亚胺的反应产物。焦谷氨酰-脯氨酰-丝氨酰-(Ne-碳-叔丁氧基)赖氨酸酰肼是通过将羰基苯并羰基焦谷氨酰-脯氨酸缩合得到羰基苯甲酰-焦谷氨酰-脯氨酸,再与丝氨酰-N-羧基苯甲酰-脯氨酰-赖氨酰甲基酯缩合而制得的赖氨酸甲酯,将其氢化得到游离的四肽酯,形成Ne -carbo-t-丁氧基-赖氨酸衍生物,并使该酯与肼反应。通过将N-三苯甲基丝氨酸与Ne-碳苯甲氧基赖氨酸甲酯缩合并使被保护的二肽去三苯甲基化来制备Seryl-Ne-碳苯甲酰赖氨酸甲酯。天冬氨酰-丙氨酰-苯基丙氨酰-异亮氨酰-甘氨酰-亮氨酰-甲硫氨酸酰胺是由羧苯并甲醛苯丙胺对硝基苯基酯和异亮氨酸甲酯通过羧-苯甲酰苯并苯丙氨酰-异亮氨酸甲基酯,羧苯甲酰-o-苄氧基天冬氨酰-异亮氨酸甲酯,羧甲基-羧甲基天冬氨酰-丙氨酰-苯丙氨酰-异亮氨酸甲酯及其酰肼和碳-叔丁氧基-天冬氨酰-丙氨酰-苯基丙氨酰-异亮氨酰-甘氨酰-亮氨酰-蛋氨酸酰胺,通过逐步添加氨基酸释放游离氨基肽,最后阶段是四肽和三肽之间的缩合。由三苯甲基-甘氨酰-亮氨酸和蛋氨酸酰胺经三苯甲基三肽酰胺制备糖基-亮氨酰-蛋氨酸酰胺。显示降压活性的药物组合物包含本发明的化合物与惰性药物载体。参考规格872332和878732。

著录项

  • 公开/公告号US3309353A

    专利类型

  • 公开/公告日1967-03-14

    原文格式PDF

  • 申请/专利权人 SANDOZ LTD.;

    申请/专利号US19620209811

  • 发明设计人 BOISSONNAS ROGER;SANDRIN EDMOND;

    申请日1962-07-11

  • 分类号C07K7/08;C07K7/16;C07K7/22;

  • 国家 US

  • 入库时间 2022-08-23 13:47:24

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号